Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deric L Wheeler

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Molecular Cancer Therapeutics|December 12, 2013
Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancerCleo E Rolle, Rajani Kanteti, Mosmi Surati, et al.
Molecular Cancer Therapeutics|April 28, 2017
Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCCAdam D Swick, Prashanth J Prabakaran, Margot C Miller, et al.
Frontiers in Oncology|May 20, 2025
Tumor-associated MerTK promotes a pro-inflammatory microenvironment and enhances immune checkpoint inhibitor response in triple-negative breast cancerBridget E Crossman, Regan L Harmon, Mari Iida, et al.
Plos One|September 22, 2010
Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinomaHiromitsu Hatakeyama, Haixia Cheng, Pamela Wirth, et al.
Oncogenesis|September 6, 2019
EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesotheliomaYi-Hung Carol Tan, Saumya Srivastava, Brian M Won, et al.
Molecular Cancer Therapeutics|July 17, 2016
Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to CetuximabMari Iida, Harsh Bahrar, Toni M Brand, et al.
Iscience|July 12, 2024
Teriflunomide/leflunomide synergize with chemotherapeutics by decreasing mitochondrial fragmentation via DRP1 in SCLCTamara Mirzapoiazova, Liz Tseng, Bolot Mambetsariev, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2015
AXL Is a Logical Molecular Target in Head and Neck Squamous Cell CarcinomaToni M Brand, Mari Iida, Andrew P Stein, et al.
Cancer Biology & Therapy|June 25, 2013
Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancerIchiro Kawada, Rifat Hasina, Frances E Lennon, et al.
Molecular Cancer Therapeutics|August 11, 2018
MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting AgentsNellie K McDaniel, Christopher T Cummings, Mari Iida, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Molecular Cancer Therapeutics|December 12, 2013
Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancerCleo E Rolle, Rajani Kanteti, Mosmi Surati, et al.
Molecular Cancer Therapeutics|April 28, 2017
Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCCAdam D Swick, Prashanth J Prabakaran, Margot C Miller, et al.
Frontiers in Oncology|May 20, 2025
Tumor-associated MerTK promotes a pro-inflammatory microenvironment and enhances immune checkpoint inhibitor response in triple-negative breast cancerBridget E Crossman, Regan L Harmon, Mari Iida, et al.
Plos One|September 22, 2010
Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinomaHiromitsu Hatakeyama, Haixia Cheng, Pamela Wirth, et al.
Oncogenesis|September 6, 2019
EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesotheliomaYi-Hung Carol Tan, Saumya Srivastava, Brian M Won, et al.
Molecular Cancer Therapeutics|July 17, 2016
Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to CetuximabMari Iida, Harsh Bahrar, Toni M Brand, et al.
Iscience|July 12, 2024
Teriflunomide/leflunomide synergize with chemotherapeutics by decreasing mitochondrial fragmentation via DRP1 in SCLCTamara Mirzapoiazova, Liz Tseng, Bolot Mambetsariev, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2015
AXL Is a Logical Molecular Target in Head and Neck Squamous Cell CarcinomaToni M Brand, Mari Iida, Andrew P Stein, et al.
Cancer Biology & Therapy|June 25, 2013
Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancerIchiro Kawada, Rifat Hasina, Frances E Lennon, et al.
Molecular Cancer Therapeutics|August 11, 2018
MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting AgentsNellie K McDaniel, Christopher T Cummings, Mari Iida, et al.
Pageof 8